GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases. The lead candidate, uproleselan, is in Phase III development for relapsed/refractory acute myeloid leukaemia. GlycoMimetics listed on NASDAQ in 2014.